Novel Coronavirus (SARS-CoV-2/COVID-19)
Clinicians who participate in a clinical trial for a drug or biological product to treat a patient with novel coronavirus may now earn credit in the Merit-based Incentive Payment System, the Centers for Medicare & Medicaid Services announced.
The Bipartisan Policy Center released a new report examining the immense challenges facing the U.S. rural health care system as highlighted by the COVID-19 pandemic.
Hospitals’ already thin margins plunged into the red in March as non-emergency procedures and revenues fell and expenses for staff, supplies and building capacity rose to prepare for a surge in COVID-19 patients, according to a new report by health care consultancy Kaufman Hall.
The Food and Drug Administration authorized the first diagnostic test with a home collection option for COVID-19.
A panel of experts convened by the National Institutes of Health released COVID-19 treatment guidelines for health care providers, which will be updated as new data become available.
The FBI warned today of specific COVID-19-themed email phishing campaigns targeting U.S.-based medical providers.
The Food and Drug Administration said that it will temporarily forgo action against 503A compounding pharmacies that provide to hospitals certain compounded drugs without patient-specific prescriptions.
AHA statement on the Paycheck Protection Program & Health Care Enhancement Act from President and CEO Rick Pollack.
Following a global increase in malicious cyber activity exploiting fear derived from the COVID-19 pandemic, the FBI was notified of targeted email phishing attempts against US-based medical providers.
The AHA urged the Department of Health and Human Services and the Health Resources and Services Administration to provide flexibility in the administration of the 340B Drug Pricing Program to better enable these hospitals to serve their communities during the COVID-19 national emergency.